News Bankruptcy threat looms as Quince runs out of options Investor panic has poleaxed Quince Therapeutics share price, after a regulatory filing revealed the biotech's cash is running out.
News Lundbeck preps phase 3 for migraine prevention drug Lundbeck seems to have brought its migraine prevention drug bocunebart back on track with positive data for an intravenous formulation.
News BridgeBio gains on phase 3 dwarfism data Shares in BridgeBio rose after it revealed data from a trial of infigratinib in achondroplasia, raising the prospect of the first oral treatment.
News Kailera, Hengrui stake claim to oral weight loss category Chasing Novo Nordisk and Eli Lilly, Kailera and Hengrui have reported 12.1% weight loss in phase 2 with their oral GIP/GLP-1 agonist ribupatide.
Patients Sponsored From insight to impact: Why the patient voice will redefine ... Is patient-centred trial design becoming a strategic advantage for mid-size pharma, helping cut risk, improve timelines, and engage patients?
News Data builds on Roche's dominance in primary progressive MS Roche looks on track to add oral BTK inhibitor fenebrutinib to treatment options for primary progressive multiple sclerosis.
News Agios mulls early FDA filing for sickle cell therapy Agios is planning to file its sickle cell disease candidate mitapivat with the FDA under the accelerated pathway within the next few months.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
